

Mark Smolkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10784295/publications.pdf>

Version: 2024-02-01

14
papers

482
citations

1163117

8
h-index

1474206

9
g-index

14
all docs

14
docs citations

14
times ranked

691
citing authors

#	ARTICLE	IF	CITATIONS
1	Helper T-Cell Responses and Clinical Activity of a Melanoma Vaccine With Multiple Peptides From MAGE and Melanocytic Differentiation Antigens. <i>Journal of Clinical Oncology</i> , 2008, 26, 4973-4980.	1.6	108
2	A Multi-peptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2008, 31, 420-430.	2.4	100
3	Immunity to Melanoma Antigens: From Self-Tolerance to Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 243-295.	2.2	55
4	A Novel Form of Breast Intraoperative Radiation Therapy With CT-Guided High-Dose-Rate Brachytherapy: Results of a Prospective Phase 1 Clinical Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 46-54.	0.8	55
5	Autoimmune Toxicities Associated with the Administration of Antitumor Vaccines and Low-Dose Interleukin-2. <i>Journal of Immunotherapy</i> , 2005, 28, 412-419.	2.4	38
6	A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. , 2014, 2, 23.		21
7	Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype. <i>Neurology</i> , 2021, 96, e1063-e1069.	1.1	21
8	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
9	PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases. <i>Human Pathology</i> , 2018, 81, 184-191.	2.0	16
10	Tubular carcinoma of the breast: Institutional and SEER database analysis supporting a unique classification. <i>Breast Disease</i> , 2015, 35, 103-111.	0.8	14
11	Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyI:CLC (Mel63). , 2021, 9, e000934.		14
12	Immunogenicity in humans of a transdermal multi-peptide melanoma vaccine administered with or without a TLR7 agonist. , 2021, 9, e002214.		11
13	Predictors of early, recurrent, and intractable seizures in low-grade glioma. <i>Neuro-Oncology Practice</i> , 2021, 8, 40-47.	1.6	9
14	Novel Risk Factors for Predicting the Development of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Undergoing Induction and Re-Induction Chemotherapy. <i>Blood</i> , 2016, 128, 5165-5165.	1.4	0